JPH0551388A - Lipid peroxide production-inhibiting agent - Google Patents
Lipid peroxide production-inhibiting agentInfo
- Publication number
- JPH0551388A JPH0551388A JP3212295A JP21229591A JPH0551388A JP H0551388 A JPH0551388 A JP H0551388A JP 3212295 A JP3212295 A JP 3212295A JP 21229591 A JP21229591 A JP 21229591A JP H0551388 A JPH0551388 A JP H0551388A
- Authority
- JP
- Japan
- Prior art keywords
- sesamin
- episesamin
- present
- lipid peroxide
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、セサミン及び／又はエ
ピセサミンを有効成分とする過酸化脂質生成抑制剤に関
する。FIELD OF THE INVENTION The present invention relates to a lipid peroxide production inhibitor containing sesamin and / or episesamin as an active ingredient.
【０００２】[0002]
【従来の技術】近年、老化速度と酸素代謝が密接に関係
していることが解明されてきた。即ち酸素から生成する
より活性な分子種である活性酸素、具体的にスーパーオ
キシドラジカル（Ｏ2 - ）、過酸化水素（Ｈ2 Ｏ2 ）、
ヒドロキシラジカル（・ＯＨ）、一重項酸素(1Ｏ2 ）の
４種の活性酸素ならびにその他フリーラジカルはその過
酸化反応性による生体組織、細胞への傷害作用が強く、
老化促進現象の主要因とされている。2. Description of the Related Art Recently, it has been clarified that the aging rate and oxygen metabolism are closely related. That is, active oxygen, which is a more active molecular species generated from oxygen, specifically superoxide radical (O 2 − ), hydrogen peroxide (H 2 O 2 ),
Hydroxyl radical (.OH), four types of active oxygen such as singlet oxygen ( 1 O 2 ) and other free radicals have a strong damaging effect on living tissues and cells due to their peroxidative reactivity,
It is considered to be the main cause of the aging acceleration phenomenon.
【０００３】例えば、生体内の酵素系や大気中の紫外線
によって誘発された活性酸素はラジカル反応によって過
酸化脂質を生成する。そして、生じた過酸化脂質は細胞
膜や細胞内オルガネラの膜を変化させ、この結果、諸臓
器組織や赤血球の機能低下や壊死が起こり、血栓症、動
脈硬化症、肝疾患、肺浮腫、皮膚疾患、眼疾患、老化
等、種々の症状として現われてくる。従って、過酸化脂
質の生成を抑制する薬剤は上記疾患の予防及び治療に重
要である。For example, active oxygen induced by an enzyme system in the living body or ultraviolet rays in the atmosphere produces a lipid peroxide by a radical reaction. The produced lipid peroxide changes the cell membrane and the membrane of intracellular organelles, resulting in functional deterioration and necrosis of various organ tissues and erythrocytes, and thrombosis, arteriosclerosis, liver disease, pulmonary edema, and skin disease. , Various symptoms such as eye diseases and aging. Therefore, agents that suppress the production of lipid peroxides are important for the prevention and treatment of the above diseases.
【０００４】このような活性酸素の消去及び過酸化脂質
の抑制剤としてはビタミンＥ、ビタミンＣあるいはビタ
ミンＢ2 など天然のビタミン類が医療に頻用されている
が、このうち、ビタミンＢ2 はグルタチオン還元酵素を
触媒し、グルタチオンレベルを高めることにより過酸化
脂質生成を抑制することが知られている。また、スパー
オキシドラジカル（Ｏ2 -）に作用しこれを消去するス
ーパーオキシドデイスムターゼ（ＳＯＤ）も注目されて
いる。さらにビタミンＥをはじめとする抗酸化剤につい
て老化とのかかわりが研究されている。Natural vitamins such as vitamin E, vitamin C or vitamin B 2 are frequently used in medical treatment as such active oxygen scavengers and lipid peroxide inhibitors. Of these, vitamin B 2 is glutathione. It is known to inhibit the production of lipid peroxides by catalyzing a reductase and increasing glutathione levels. In addition, superoxide dismutase (SOD), which acts on and eliminates the superoxide radical (O 2 − ), is also drawing attention. Furthermore, the relationship between aging and antioxidants such as vitamin E has been studied.
【０００５】一方、近年、種々の抗酸化性物質が知られ
ているが、例えば、特開昭６２−２３０７８６号公報や
特開昭６２−５８１号公報には胡麻に含まれているフェ
ノール性の天然抗酸化性物質として、セサミノールや２
−（３，４−メチレンジオキシフェニル）−６−（３−
メトキシ−４−ヒドロキシフェニル）−３，７−ジオキ
サビシクロ〔３，３，０〕オクタンや２−（３，４−メ
チレンジオキシフェニル）−６−（３−メトキシ−４−
ヒドロキシフェノキシ）−３，７−ジオキサビシクロ
〔３，３，０〕オクタンや２，６−ビス−（３−メトキ
シ−４−ヒドロキシフェニル）−３，７−ジオキサビシ
クロ〔３，３，０〕オクタンが開示されている。On the other hand, in recent years, various antioxidative substances have been known. For example, in JP-A-62-230786 and JP-A-62-581, the phenolic compounds contained in sesame are disclosed. As natural antioxidants, sesaminol and 2
-(3,4-methylenedioxyphenyl) -6- (3-
Methoxy-4-hydroxyphenyl) -3,7-dioxabicyclo [3,3,0] octane and 2- (3,4-methylenedioxyphenyl) -6- (3-methoxy-4-)
Hydroxyphenoxy) -3,7-dioxabicyclo [3,3,0] octane and 2,6-bis- (3-methoxy-4-hydroxyphenyl) -3,7-dioxabicyclo [3,3,0] ] Octane is disclosed.
【０００６】しかしながら、胡麻中に含まれている上記
以外の物質であるセサミンやエピセサミンに関してはそ
の抗酸化能について一切、示唆されていない。そこで、
安全性が高く、過酸化脂質の生成を抑制し、血栓症等の
疾患や老化の予防や治療のための薬剤の開発が強く望ま
れている。However, regarding the substances other than the above-mentioned substances such as sesamin and episesamin contained in sesame, the antioxidative ability thereof has not been suggested at all. Therefore,
There is a strong demand for the development of a drug that is highly safe, suppresses the production of lipid peroxide, and prevents or treats diseases such as thrombosis and aging.
【０００７】[0007]
【発明が解決しようとする課題】従って本発明は、新規
な過酸化脂質生成抑制剤を提供しようとするものであ
る。Therefore, the present invention is intended to provide a novel lipid peroxide production inhibitor.
【０００８】[0008]
【課題を解決するための手段】本発明者等は、上記の目
的を達成するため種々研究した結果、胡麻種子、胡麻粕
及び胡麻油中より単離した又は合成により得られたセサ
ミン及び／又はエピセサミンが生体外では全く抗酸化能
を示さないものの生体内では有効に働き過酸化脂質の生
成を抑制するという全く新しい事実を見出し本発明を完
成した。本発明において使用するセサミン及びエピセサ
ミンは胡麻中に約０．５％含まれていて供給面で実用性
に富み、しかも安全性が高い。従って本発明は、セサミ
ン及び／又はエピセサミンを有効成分とする過酸化脂質
生成抑制剤を提供しようとするものである。Means for Solving the Problems The present inventors have conducted various studies in order to achieve the above-mentioned object, and as a result, sesamin and / or episesamin isolated from sesame seeds, sesame meal and sesame oil or obtained by synthesis are obtained. The present invention has completed the present invention by discovering a completely new fact that it has no antioxidative ability in vitro, but effectively acts in vivo to suppress the production of lipid peroxide. The sesamin and episesamin used in the present invention are contained in sesame in an amount of about 0.5%, which is highly practical in terms of supply and highly safe. Therefore, the present invention aims to provide a lipid peroxide production inhibitor containing sesamin and / or episesamin as an active ingredient.
【０００９】[0009]
【具体的な説明】本発明で使用するセサミン及びエピセ
サミンはこれらを単独で、または混合して使用すること
ができる。本発明の有効成分であるセサミン及びエピセ
サミン並びに該化合物を主成分とする抽出物を得る方法
として次の手順で行うことができる。まず、本発明の有
効成分である化合物を主成分とする抽出物を胡麻油から
得るには、胡麻油とは実質的に非混和性であり且つ本発
明の有効成分である化合物を抽出・溶解することができ
る種々の有機溶剤を用いて抽出・濃縮することで得られ
る。このような有機溶剤として、例えばアセトン、メチ
ルエチルケトン、ジエチルケトン、メタノール、エタノ
ール等を挙げることができる。DETAILED DESCRIPTION The sesamin and episesamin used in the present invention can be used alone or in combination. As a method for obtaining sesamin and episesamin, which are the active ingredients of the present invention, and an extract containing the compound as a main component, the following procedure can be performed. First, in order to obtain an extract containing a compound as an active ingredient of the present invention as a main component from sesame oil, a compound that is substantially immiscible with sesame oil and is an active ingredient of the present invention is extracted and dissolved. It can be obtained by extraction and concentration using various organic solvents capable of Examples of such an organic solvent include acetone, methyl ethyl ketone, diethyl ketone, methanol, ethanol and the like.
【００１０】本発明の有効成分である化合物を主成分と
する抽出物を得るには、例えば胡麻油と上記の溶剤のい
ずれかとを均一に混合した後、低温において静置し、遠
心分離等の常法に従って相分離を行い、溶剤画分から溶
剤を蒸発除去することにより得られる。さらに具体的に
は、胡麻油を２〜１０倍、好ましくは６〜８倍容量のア
セトンに溶かし、−８０℃で一晩放置する。その結果油
成分が沈澱となり、濾過により得た濾液から有機溶剤を
留去して、本発明化合物を主成分とする抽出物が得られ
る。あるいは、胡麻油を熱メタノール又は熱エタノール
で混合した後、室温において静置し、溶剤画分から溶剤
を蒸発除去することにより得られる。In order to obtain an extract containing a compound as an active ingredient of the present invention as a main component, for example, sesame oil and one of the above-mentioned solvents are uniformly mixed, and then the mixture is allowed to stand at a low temperature, followed by centrifugation or the like. It is obtained by performing phase separation according to the method and evaporating and removing the solvent from the solvent fraction. More specifically, sesame oil is dissolved in 2 to 10 times, preferably 6 to 8 times the volume of acetone and left overnight at -80 ° C. As a result, the oil component becomes a precipitate, and the organic solvent is distilled off from the filtrate obtained by filtration to obtain an extract containing the compound of the present invention as the main component. Alternatively, it can be obtained by mixing sesame oil with hot methanol or hot ethanol, allowing to stand at room temperature, and removing the solvent from the solvent fraction by evaporation.
【００１１】さらに具体的には、胡麻油を２〜１０倍、
好ましくは５〜７倍容量の熱メタノール（５０℃以上）
又は熱エタノール（５０℃以上）で混合し激げしく抽出
する。室温に静置あるいは遠心分離等の常法に従って相
分離を行い、溶剤画分から溶剤を留去して、本発明化合
物を主成分とする抽出物が得られる。又超臨界ガス抽出
も利用できる。この抽出物より、各々の本発明化合物を
得るためには、抽出物をカラムクロマトグラフィー、高
速液体クロマトグラフィー、再結晶、蒸留、液々交流分
配クロマトグラフィー等の常法に従って処理することに
より目的とする化合物を単離すればよい。More specifically, sesame oil is added 2 to 10 times,
Preferably 5 to 7 volumes of hot methanol (50 ° C or higher)
Alternatively, mix with hot ethanol (50 ° C or more) and extract violently. Phase separation is performed according to a conventional method such as standing at room temperature or centrifugation, and the solvent is distilled off from the solvent fraction to obtain an extract containing the compound of the present invention as a main component. Supercritical gas extraction can also be used. In order to obtain each of the compounds of the present invention from this extract, the objective is to treat the extract according to a conventional method such as column chromatography, high performance liquid chromatography, recrystallization, distillation, and liquid-liquid exchange partition chromatography. The compound to be isolated may be isolated.
【００１２】さらに具体的には、逆相カラム（５
Ｃ10）、溶離液にメタノール／水（６０：４０）を使っ
て、上記抽出物を高速液体クロマトグラフィーで分取
し、溶媒を留去した後、得られた結晶をエタノールで再
結晶化することでセサミン及び／又はエピセサミンの各
本発明の有効成分である化合物が得られる。More specifically, the reversed-phase column (5
C 10 ), using methanol / water (60:40) as an eluent, the above extract is separated by high performance liquid chromatography, the solvent is distilled off, and the obtained crystals are recrystallized with ethanol. Thus, each compound of sesamin and / or episesamin, which is an active ingredient of the present invention, can be obtained.
【００１３】用いる胡麻油は精製品でもよく、また胡麻
油の製造過程で脱色工程前のいずれの粗製品でもよくさ
らに、胡麻種子あるいは胡麻粕（脱脂胡麻種子、残油分
８〜１０％）であってもよい。この場合、胡麻種子ある
いは胡麻粕を必要により破砕した後、任意の溶剤、例え
ば胡麻油からの抽出について前記した溶剤を用いて常法
により抽出することができる。抽出残渣を分離した後、
抽出液から蒸発等により溶剤を除去することにより抽出
物が得られる。The sesame oil used may be a refined product, any crude product before the decoloring step in the process of producing sesame oil, and further sesame seeds or sesame meal (defatted sesame seeds, residual oil content 8 to 10%). Good. In this case, sesame seeds or sesame meal can be crushed if necessary, and then extracted by a conventional method using any solvent, for example, the solvent described above for extraction from sesame oil. After separating the extraction residue,
An extract is obtained by removing the solvent from the extract by evaporation or the like.
【００１４】このように調製された胡麻種子抽出物、胡
麻粕抽出物あるいは粗製品の胡麻油抽出物よりセサミン
及び／又はエピセサミンの各本発明の有効成分である化
合物が同様の手法で得られる。なお、細辛から得られる
セサミンも胡麻種子、胡麻粕及び胡麻油より得られるセ
サミンと同等の効果を有し、これら光学活性体も本願発
明に含まれる。さらに、胡麻油製造過程の副産物からも
本発明の有効成分である化合物を得ることができる。From the sesame seed extract, sesame meal extract or crude sesame oil extract thus prepared, sesamin and / or episesamin, which are the active ingredients of the present invention, can be obtained by the same method. It should be noted that sesamin obtained from spicy sponge has the same effect as sesamin obtained from sesame seed, sesame meal and sesame oil, and these optically active substances are also included in the present invention. Furthermore, the compound which is the active ingredient of the present invention can be obtained from the by-product of the sesame oil production process.
【００１５】なお、本発明の有効成分であるセサミン及
びエピセサミンの精製法及び抽出物を得る方法は、これ
に限られるものではない。さらに、上記本発明の有効成
分化合物及び本発明化合物を主成分とする抽出物は胡麻
油、胡麻粕、及び胡麻種子から得たものに限定したわけ
ではなく、上記本発明の化合物を含む天然物をすべて使
用できるのは明らかであり、例えば五加皮、桐木、白果
樹皮、ヒハツ、細辛等をあげることができる。The method for purifying sesamin and episesamin, which are the active ingredients of the present invention, and the method for obtaining an extract are not limited to these. Further, the active ingredient compound of the present invention and the extract containing the compound of the present invention as the main component are not limited to those obtained from sesame oil, sesame meal, and sesame seeds, and natural products containing the compound of the present invention may be used. It is obvious that they can all be used, and examples thereof include Goka hide, paulownia wood, white fruit bark, hihatsu, and spicy spices.
【００１６】また、合成によりセサミン及び／又はエピ
セサミンを得ることもできる。例えば、セサミン及び／
又はエピセサミンについてBerozaらの方法〔J.Am.Chem.
Soc.78, 1242(1956)〕で合成することができる。本発明
の過酸化脂質生成抑制剤は、経口投与することができ、
又は非経口投与、例えば筋肉内注射、皮下注射、静脈内
注射等により投与することもできる。It is also possible to obtain sesamin and / or episesamin by synthesis. For example, sesamin and /
Alternatively, the method of Beroza et al. [J. Am. Chem.
Soc. 78 , 1242 (1956)]. The lipid peroxide production inhibitor of the present invention can be orally administered,
Alternatively, it can be administered parenterally, for example, by intramuscular injection, subcutaneous injection, intravenous injection and the like.
【００１７】投与量は、投与の目的、投与対象者の状態
等により異るが、経口投与の場合一般に１〜１００mg／
日、非経口投与の場合は０．１〜２０mg／日である。例
えば、注射剤を調製する場合、医薬品用の可溶化剤を、
例えば、非イオン界面活性剤等を利用することができ
る。さらに具体的には、本発明化合物を８０倍容量のＰ
ＯＥ（６０）硬化ヒマシ油あるいは、ＰＯＥソルビタン
モノオレート等の非イオン界面活性剤に加熱溶解させ、
生理食塩水で希釈することで調製することができ、適宜
等張化剤、安定剤、防腐剤、無痛化剤を加えてもよい。
さらに、必要に応じて乳液状製剤、カプセル剤、散剤、
顆粒剤、錠剤等を調製することができる。The dose varies depending on the purpose of administration, the condition of the recipient, and the like, but generally 1 to 100 mg / oral for oral administration.
Daily, 0.1 to 20 mg / day for parenteral administration. For example, when preparing an injection, a solubilizer for pharmaceuticals
For example, a nonionic surfactant or the like can be used. More specifically, the compound of the present invention is mixed with 80 times the volume of P.
OE (60) hydrogenated castor oil or POE sorbitan monooleate and the like dissolved by heating in a nonionic surfactant,
It can be prepared by diluting with a physiological saline solution, and an isotonic agent, a stabilizer, a preservative, and a soothing agent may be added appropriately.
Furthermore, if necessary, an emulsion formulation, capsule, powder,
Granules, tablets and the like can be prepared.
【００１８】本発明はまた、セサミン及び／又はエピセ
サミンを添加して成る、過酸化脂質生成抑制のための飲
食物に関する。又、本発明の有効成分である化合物は、
従来食品中より見出した化合物であるので安全性の面か
らも優れているのは明らかである。これはまた、７週令
のＩＣＲ雄性マウスに対し、セサミン２．１４ｇ／day
／kgを２週間連投（経口投与）したところ、何ら異常な
症状は認められなかったことからも明らかである。The present invention also relates to a food or drink for suppressing the production of lipid peroxide, which is obtained by adding sesamin and / or episesamin. Further, the compound which is the active ingredient of the present invention is
Since it is a compound found in conventional foods, it is clearly superior in terms of safety. It was also shown to sesamin 2.14 g / day for 7 week old ICR male mice.
It is also clear from the fact that no abnormal symptom was observed when 2 kg / kg was continuously administered (orally administered) for 2 weeks.
【００１９】本発明の化合物を添加する食品の種類は特
に限定されない。さらに、本発明化合物を含有する飲食
物において、セサミン及び／又はエピセサミンの使用量
については特に制限はないが、含有する食品に対してセ
サミン及び／又はエピセサミンを合計０．０００１重量
％以上、特に、０．００１重量％以上が好ましい。さら
に、セサミン及び／又はエピセサミンを含有する抽出物
を使用する場合には、０．０００４重量％以上、特に
０．００４重量％以上が好ましい。The type of food to which the compound of the present invention is added is not particularly limited. Furthermore, in food and drink containing the compound of the present invention, there is no particular limitation on the amount of sesamin and / or episesamin used, but a total of 0.0001% by weight or more of sesamin and / or episesamin relative to the food containing it, particularly, It is preferably 0.001% by weight or more. Furthermore, when an extract containing sesamin and / or episesamin is used, 0.0004% by weight or more, particularly 0.004% by weight or more is preferable.
【００２０】[0020]
【実施例】次に、実施例により、この発見をさらに具体
的に説明する。試験例１ ４週令（１３９ｇ）の雄ウィスター系ラットを１群６匹
とし、２群に分けた。ひとつのグループは、２０％カゼ
イン、１０％コーン油、１％ビタミン混合物（ＡｌＮ−
ＴＭ）、３．５％ミネラル混合物（ＡｌＮ−ＴＭ）、
０．２％重酒石酸コリン、０．３％ＤＬ−メチオニン、
５％セルロース、１５％コーンスターチ、０．５％コレ
ステロール及び４４．５％シュクロースからなるコレス
テロール食で飼育した。EXAMPLES Next, this finding will be described more specifically by way of examples. Test Example 1 Four-week-old (139 g) male Wistar rats were divided into two groups, each group consisting of 6 rats. One group is 20% casein, 10% corn oil, 1% vitamin mixture (AlN-
TM), 3.5% mineral mixture (AlN-TM),
0.2% choline bitartrate, 0.3% DL-methionine,
They were raised on a cholesterol diet consisting of 5% cellulose, 15% corn starch, 0.5% cholesterol and 44.5% sucrose.
【００２１】そして、残りの１グループはシュクロース
を減じて、精製したセサミン及びエピセサミン混合物
（セサミン：５１．３％、エピセサミン：４７．８％）
を０．２％加えたセサミン食で飼育した。４週間後、血
清中の過酸化脂質をＴＢＡ法で測定した。コレステロー
ル食及びセサミン食で飼育したラットの過酸化脂質はそ
れぞれ５．３４±０．６４及び１．９１±０．２３（nm
ol／ml）となり、セサミンが過酸化脂質の生成を抑制す
ることが認められた。The remaining one group is a mixture of refined sesamin and episesamin with sucrose reduced (sesamin: 51.3%, episesamin: 47.8%).
Were bred with a sesamin diet containing 0.2% of. After 4 weeks, lipid peroxide in serum was measured by the TBA method. Rats fed a cholesterol diet and a sesamin diet had lipid peroxides of 5.34 ± 0.64 and 1.91 ± 0.23 (nm
ol / ml), and sesamin was confirmed to suppress the production of lipid peroxide.
【００２２】試験例２ ４週令（１００ｇ）の雄ウィスター系ラットを１群６匹
とし、４群に分けた。ひとつのグループは、普通食（市
販タイプＮＭＦ、オリエンタル酵母）と飲み水として水
道水で４週間飼育した。残りの３グループは飲み水とし
てアルコール溶液を与えた（最初の８日間は３％エタノ
ール溶液、次の８日間は５％エタノール溶液、残り１２
日間は７．５％エタノール溶液）。アルコールを与えた
３グループの内、２グループは普通食にグルタチオンを
０．４％あるいは実施例１で使用したセサミン及びエピ
セサミン混合物０．５％加えた飼料で飼育した。実験群
を次のように設定した。 Test Example 2 Four-week-old (100 g) male Wistar rats were divided into 4 groups, each group consisting of 6 rats. One group was bred for 4 weeks with normal food (commercial type NMF, oriental yeast) and tap water as drinking water. The remaining 3 groups were given alcoholic solution as drinking water (3% ethanol solution for the first 8 days, 5% ethanol solution for the next 8 days, 12 remaining).
7.5% ethanol solution for a day). Of the 3 groups fed with alcohol, 2 groups were fed with normal diet containing 0.4% of glutathione or 0.5% of the mixture of sesamin and episesamin used in Example 1. The experimental group was set up as follows.
【００２３】 １．普通食 飲料 水道水 ２．普通食 飲料 アルコール
溶液 ３．普通食＋０．４％グルタチオン 飲料 アルコール
溶液 ４．普通食＋０．５％セサミン 飲料 アルコール
溶液 ４週間後、摂食量、摂水量、体重増加量、血清及び肝臓
中の過酸化脂質量を測定した。結果を表１に示す。セサ
ミンが過酸化脂質の生成を抑制することが認められた。1. Ordinary food Drinking tap water 2. Ordinary food Beverage Alcohol solution 3. Normal food + 0.4% glutathione beverage Alcohol solution 4. Ordinary food + 0.5% sesamin drink alcohol solution After 4 weeks, food intake, water intake, body weight gain, and lipid peroxide levels in serum and liver were measured. The results are shown in Table 1. It was found that sesamin suppressed the production of lipid peroxide.
【００２４】[0024]
【表１】 [Table 1]
【００２５】試験例３ ５週令の雌ウィスター系ラットを１群１５匹とし、２群
に分けた。ひとつのグループは、２０％カゼイン、５％
コーン油、１％ビタミン混合物（ＡｌＮ−ＴＮ）、２．
５％ミネラル混合物（ＡｌＮ−ＴＭ）、０．２％重酒石
酸コリン、０．３％ＤＬ−メチオニン、５％セルロー
ス、１５％コンスターチ及び５１％シュクロースからな
る普通食で飼育した。そして、残りの１グループはシュ
クロースを減じて、実施例１で使用したセサミン及びエ
ピセサミン混合物を０．２％加えたセサミン食で飼育し
た。 Test Example 3 Five-week-old female Wistar rats were divided into two groups, each group consisting of 15 rats. One group is 20% casein, 5%
Corn oil, 1% vitamin mixture (AlN-TN), 2.
They were fed a normal diet consisting of 5% mineral mixture (AlN-TM), 0.2% choline bitartrate, 0.3% DL-methionine, 5% cellulose, 15% corn starch and 51% sucrose. Then, the remaining one group was fed with a sesamin diet containing 0.2% of the sesamin and episesamin mixture used in Example 1 with sucrose reduced.
【００２６】飼育１週間目に、発癌誘発剤（７，１２−
ジメチルベンズ（ａ）アントラセン：ＤＭＢＡ）１０mg
をコーン油１mlに溶かしチューブで胃内に投与した。１
２週間後、血清、肝臓及び腫瘍中の過酸化脂質を測定し
た。結果を表２に示す。 表 ２ ─────────────────────────────── 過 酸 化 脂 質 濃 度 血 清 肝 臓 腫 瘍 （nmol／ml） （nmol／g liver) （nmol／g tumor) 普通食 9.94±1.68 a 577.3±23.7 a 206.5±14.1 a セサミン食 4.99±0.49 b 483.6±27.0 b 150.0±9.9 b ─────────────────────────────── セサミンが過酸化脂質の生成を抑制することが認められ
た。A carcinogenic agent (7,12-
Dimethylbenz (a) anthracene: DMBA) 10 mg
Was dissolved in 1 ml of corn oil and administered into the stomach by a tube. 1
Two weeks later, lipid peroxide in serum, liver and tumor was measured. The results are shown in Table 2. Table 2 ─────────────────────────────── peracid of lipid concentration serum liver tumors (nmol / ml ) (Nmol / g liver) (nmol / g tumor) Normal diet 9.94 ± 1.68 a 577.3 ± 23.7 a 206.5 ± 14.1 a Sesamin diet 4.99 ± 0.49 b 483.6 ± 27.0 b 150.0 ± 9.9 b ────────── ────────────────────── It was observed that sesamin suppresses the production of lipid peroxides.
【００２７】実施例１ バター製造工程の攪動操作（チャーニング）でバターミ
ルクが除かれた、バター脂肪１００ｇに実施例１で使用
したセサミン及びエピセサミン混合物を２．４ｇ加えて
練圧操作（ワーキング）を行い均等な組成として本発明
化合物含有老化防止バターを得た。 Example 1 2.4 g of the mixture of sesamin and episesamin used in Example 1 was added to 100 g of butter fat from which butter milk had been removed by the agitating operation (charging) in the butter production process (working). The antiaging butter containing the compound of the present invention was obtained as a uniform composition.
【００２８】実施例２ 本発明化合物０．５ｇを無水ケイ酸２０．５ｇと混合
し、これにトウモロコシデンプン７９ｇを加え、更に混
合した。この化合物に１０％ハイドロキシプロピルセル
ロース・エタノール溶液１００mlを加え、常法通り捏和
し、押し出し、乾燥して顆粒剤を得た。 Example 2 0.5 g of the compound of the present invention was mixed with 20.5 g of silicic acid anhydride, 79 g of corn starch was added thereto, and further mixed. To this compound was added 100 ml of 10% hydroxypropylcellulose / ethanol solution, which was kneaded, extruded and dried in the usual way to give granules.
【００２９】実施例３ 本発明化合物７ｇを無水ケイ酸２０ｇと混合し、これに
微結晶セルロース１０ｇ、ステアリン酸マグネシウム
３．０ｇ、乳糖６０ｇを加え混合し、この混合物を単発
式打錠機にて打錠して径７mm、重量１００mgの錠剤を製
造した。 Example 3 7 g of the compound of the present invention was mixed with 20 g of silicic acid anhydride, 10 g of microcrystalline cellulose, 3.0 g of magnesium stearate and 60 g of lactose were added and mixed, and this mixture was mixed with a single-shot tableting machine. A tablet having a diameter of 7 mm and a weight of 100 mg was produced by tableting.
【００３０】実施例４ 本発明化合物２．５ｇを非イオン界面活性剤であるＴＯ
−１０Ｍ（日光ケミカルズ）２００ｇに１２２℃で加熱
溶解し、これに６０℃に加温した滅菌生理食塩水４．７
９７５ｌを加えてよく攪拌し、これを無菌的にバイアル
に分配し、密封して注射剤を製造した。 Example 4 2.5 g of the compound of the present invention was mixed with TO as a nonionic surfactant.
Sterile physiological saline solution 4.7 which was dissolved in 200 g of -10M (Nikko Chemicals) by heating at 122 ° C and heated to 60 ° C.
975 l was added and well stirred, and this was aseptically distributed into vials and sealed to prepare an injection.
Claims (2)
成分とする過酸化脂質生成抑制剤。1. A lipid peroxide production inhibitor containing sesamin and / or episesamin as an active ingredient.
成分とする老化防止剤。2. An anti-aging agent containing sesamin and / or episesamin as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3212295A JPH0551388A (en) | 1991-08-23 | 1991-08-23 | Lipid peroxide production-inhibiting agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3212295A JPH0551388A (en) | 1991-08-23 | 1991-08-23 | Lipid peroxide production-inhibiting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0551388A true JPH0551388A (en) | 1993-03-02 |
Family
ID=16620218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3212295A Pending JPH0551388A (en) | 1991-08-23 | 1991-08-23 | Lipid peroxide production-inhibiting agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0551388A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016682A1 (en) * | 2004-08-09 | 2006-02-16 | Suntory Limited | Ameliorant for blood vessel elasticity and use thereof |
| WO2007037385A1 (en) | 2005-09-30 | 2007-04-05 | Suntory Limited | Method and apparatus for producing episesamin-rich composition |
| WO2007114013A1 (en) | 2006-03-31 | 2007-10-11 | Suntory Limited | Composition containing lignan compound |
| WO2008044550A1 (en) | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
| WO2008126587A1 (en) * | 2007-03-15 | 2008-10-23 | Suntory Holdings Limited | Anti-fatigue agent |
| WO2010058795A1 (en) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | Antioxidant |
| JP2010285427A (en) * | 2009-05-12 | 2010-12-24 | Suntory Holdings Ltd | Medicament for sleep disorders |
| JP2013039082A (en) * | 2011-08-18 | 2013-02-28 | Kadoya Sesami Mills Inc | Water-dispersible sesamin powder and method for producing the same |
| US8486899B2 (en) | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| JP5450075B2 (en) * | 2007-09-19 | 2014-03-26 | サントリーホールディングス株式会社 | Composition containing sesamin and vitamin B1 |
| US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
| US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
| WO2021205975A1 (en) * | 2020-04-09 | 2021-10-14 | サントリーホールディングス株式会社 | Composition for suppressing cellular senescence, and method for suppressing cellular senescence |
| WO2021230146A1 (en) * | 2020-05-11 | 2021-11-18 | サントリーホールディングス株式会社 | Composition containing sesamin or like and nr and/or nmn |
| WO2023063230A1 (en) * | 2021-10-13 | 2023-04-20 | サントリーホールディングス株式会社 | Composition containing sesamin and ergothioneine or salt thereof |
-
1991
- 1991-08-23 JP JP3212295A patent/JPH0551388A/en active Pending
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006016682A1 (en) * | 2004-08-09 | 2006-02-16 | Suntory Limited | Ameliorant for blood vessel elasticity and use thereof |
| US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
| WO2007037385A1 (en) | 2005-09-30 | 2007-04-05 | Suntory Limited | Method and apparatus for producing episesamin-rich composition |
| US7943663B2 (en) | 2005-09-30 | 2011-05-17 | Suntory Holdings Limited | Process and an apparatus for producing episesamin-rich compositions |
| US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
| WO2007114013A1 (en) | 2006-03-31 | 2007-10-11 | Suntory Limited | Composition containing lignan compound |
| US9408803B2 (en) | 2006-03-31 | 2016-08-09 | Suntory Holdings Limited | Compositions containing lignan-class compounds |
| WO2008044550A1 (en) | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
| WO2008126587A1 (en) * | 2007-03-15 | 2008-10-23 | Suntory Holdings Limited | Anti-fatigue agent |
| JP5591533B2 (en) * | 2007-03-15 | 2014-09-17 | サントリーホールディングス株式会社 | Anti-fatigue |
| TWI465235B (en) * | 2007-03-15 | 2014-12-21 | Suntory Holdings Ltd | Anti-fatigue agent |
| KR101525264B1 (en) * | 2007-03-15 | 2015-06-02 | 산토리 홀딩스 가부시키가이샤 | Anti-fatigue agent |
| US9609884B2 (en) | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
| JP5450075B2 (en) * | 2007-09-19 | 2014-03-26 | サントリーホールディングス株式会社 | Composition containing sesamin and vitamin B1 |
| JP2014055148A (en) * | 2007-09-19 | 2014-03-27 | Suntory Holdings Ltd | Compositions incorporating sesamin-class compounds and vitamin b1 class compounds |
| US8703789B2 (en) | 2007-09-19 | 2014-04-22 | Suntory Holdings Limited | Compositions incorporating sesamin-class compounds and vitamin B1 class compounds |
| US8470807B2 (en) | 2008-11-19 | 2013-06-25 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| US8486899B2 (en) | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
| WO2010058795A1 (en) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | Antioxidant |
| JP2010285427A (en) * | 2009-05-12 | 2010-12-24 | Suntory Holdings Ltd | Medicament for sleep disorders |
| JP2015110655A (en) * | 2009-05-12 | 2015-06-18 | サントリーホールディングス株式会社 | Medicament for sleep disorder |
| JP2013039082A (en) * | 2011-08-18 | 2013-02-28 | Kadoya Sesami Mills Inc | Water-dispersible sesamin powder and method for producing the same |
| WO2021205975A1 (en) * | 2020-04-09 | 2021-10-14 | サントリーホールディングス株式会社 | Composition for suppressing cellular senescence, and method for suppressing cellular senescence |
| CN115315197A (en) * | 2020-04-09 | 2022-11-08 | 三得利控股株式会社 | Composition for inhibiting cell aging and method for inhibiting cell aging |
| WO2021230146A1 (en) * | 2020-05-11 | 2021-11-18 | サントリーホールディングス株式会社 | Composition containing sesamin or like and nr and/or nmn |
| WO2023063230A1 (en) * | 2021-10-13 | 2023-04-20 | サントリーホールディングス株式会社 | Composition containing sesamin and ergothioneine or salt thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5337855B2 (en) | Method for producing ceramidase inhibitor | |
| JPH0551388A (en) | Lipid peroxide production-inhibiting agent | |
| EP0818196B1 (en) | Capsule, containing dioxabicyclo(3.3.0)octane compounds | |
| JP3283274B2 (en) | New composition | |
| EP0488513B1 (en) | Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol. | |
| EP0729753B1 (en) | Use of dioxabicyclo[3.3.0]actanes for treatment and prevention of cerebral apoplexy | |
| JPH06227977A (en) | Active oxygen eliminating agent | |
| JPH06312924A (en) | Utilization of humulones having antioxidant action | |
| US20080102082A1 (en) | Formulation for Oral Administration Having a Health-Promoting Effect on the Cardiovascular System | |
| US7767236B2 (en) | Plant seed extract composition and process for producing the same | |
| JP3075358B2 (en) | Liver function improver | |
| JPS60224629A (en) | Inhibitor composition for in vivo lipoperoxide formation | |
| KR102519649B1 (en) | Composition for the prevention or treatment of prostate-related disease comprising Rhodiola sachalinensis root extract containing kaempferol and epicatechin gallate | |
| JP5122147B2 (en) | 2- (2-Methylpropanoyl) phloroglucinol-1,5-di-O-β-D-glucopyranoside having antioxidant activity | |
| JP3977889B2 (en) | Drugs containing buckwheat husk extract as an active ingredient | |
| KR19990071183A (en) | Honggyeongcheon Extract with Efficacy and Prevention of Circulatory Diseases | |
| JPH0543458A (en) | Breast cancer-inhibiting agent | |
| JP3075360B2 (en) | Cholesterol lowering drugs | |
| JP5122148B2 (en) | 2-Acylphloroglucinol-4,6-di-C-β-D-glucopyranoside having antioxidant activity | |
| KR20070108291A (en) | Food for the prevention or alleviation of allergy symptoms and method for the preparation thereof | |
| JPH0820544A (en) | Reactive oxygen eliminator and food products and cosmetics formulated therewith | |
| JP2019535652A (en) | Composition for improving cognitive function comprising a novel quercetin compound | |
| JP5774839B2 (en) | Macrophage foaming inhibitor in arteriosclerotic tissue | |
| EP1402886B1 (en) | Lipolysis accelerator for reducing body weight and medicinal use | |
| WO2023192372A1 (en) | Methods of treating sjögren-larssen syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20041222 |
|
| A131 | Notification of reasons for refusal |
Effective date: 20050111 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050314 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060124 |
|
| A61 | First payment of annual fees (during grant procedure) |
Effective date: 20060206 Free format text: JAPANESE INTERMEDIATE CODE: A61 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 4 Free format text: PAYMENT UNTIL: 20100224 |
|
| LAPS | Cancellation because of no payment of annual fees |